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Quality of life assessment in elderly patients with
aggressive non-Hodgkin’s Lymphoma treated
with anthracycline-containing regimens.
Report of a prospective study
by the Intergruppo Italiano Linfomi
It is not only the effectiveness of treat-ment that must be evaluated in patients,who due to their age do not have very
high chances of long-term survival, but also
the type of life they are offered during and
after chemotherapy. Based on different
approaches, elderly patients with non-
Hodgkin’s lymphoma (NHL) can be treated
with the same type of regimens as younger
patients, using full dosages of drugs,1-5 or
trying to adapt the traditional chemothera-
py treatments to them by reducing the
dosage of the drugs6 or creating treatments
designed specifically for the elderly7-11 with
the aim of limiting the risk of treatment-
related toxicity and mortality. Several recent
studies concluded that the gold standard
should be considered full dose CHOP with or
without anti-CD20 monoclonal antibody,
even for elderly patients.1-5 In 1996 the Inter-
gruppo Italiano Linfomi (IIL) started a
prospective trial which compared a CHOP-
derived regimen (mini-CEOP) with a
MACOP-B-derived therapy (P-VEBEC) for the
treatment of elderly patients with aggressive
NHL.12 In addition to the traditional end-
points relating to the effectiveness of the
therapies, the study also evaluated the issue
of quality of life (QOL) following chemother-
apy. QOL has already been evaluated in
patients suffering from both aggressive and
indolent NHL13-17 but no study concentrating
on a group of elderly patients has ever been
published in extenso.
Design and Methods
Between June 1996 and December 1999,
264 (232 evaluable for final assessment)
patients over 65 years old with diffuse large
cell non-Hodgkin’s lymphoma were enrolled
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Background and Objectives. The aim of this study was to evaluate quality of life (QOL)
in a group of elderly patients (> 65 years) with aggressive non-Hodgkin's lymphoma (NHL)
treated with chemotherapy regimens containing anthracyclines.
Design and Methods. QOL was evaluated in a population of elderly patients with
aggressive NHL enrolled in a phase III clinical trial run by the Intergruppo Italiano Linfo-
mi (IIL) from 1996 to 1999 to compare two different anthracycline-containing regimens
(mini-CEOP vs P-VEBEC). The EORTC-QLQ-C30 questionnaire, which has already been
validated in oncology, was used. The questionnaire was administered at the time of diag-
nosis, half way through the chemotherapy and at the time of restaging. 
Results. Ninety-one patients completed pre-therapy and post-therapy questionnaires
and they are the subject of this report. Baseline QOL assessment showed a strong corre-
lation of poor values of QOL with anemia and high risk according to the International Prog-
nostic Index (IPI). At the end of treatment no functional scales showed worse values. A
significant improvement was observed for pain (p=0.003), appetite (p=0.006), sleep
(p=0.015) and global health (p=0.027). Considering only the 50 patients who achieved a
complete remission (CR), an improvement was also recorded for emotional state (p=0.10),
role (p=0.05), constipation (p=0.04) and global QOL (p=0.05).
Interpretation and Conclusions. The EORTC-QLQ-C30 is feasible even in a population
of  elderly patients, in whom it had never been tested before. The improvement of QOL at
the end of the treatment demonstrated that the symptoms of the disease have a greater
negative influence on the patient's life than do the side effects of the therapy. 
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in a co-operative phase III trial conducted by the Inter-
gruppo Italiano Linfomi and randomly assigned to one
of two chemotherapy regimens, mini-CEOP (cyclo-
phosphamide, 750 mg/m2, day 1; epidoxorubicin  50
mg/m2, day 1; vinblastine 5 mg/m2, day 1; prednisone
60 mg/m2, days 1-5; every 21 days for 4-6 cycles) or
P-VEBEC (epidoxorubicin 50 mg/m2 and cyclophos-
phamide 300 mg/m2, and etoposide 100 mg/m2, days
1, 15, 29, and 43; vinblastine 5 mg/m2 and bleomycin
5 mg/m2 day 22, 36, and 50; prednisone 50 mg/m2,
days 1-15). Other criteria for inclusion in the clinical
trial were Ann-Arbor stage II bulky-IV, absence of con-
comitant neoplasms, HIV negativity, good cardiac,
renal and respiratory function and no previous treat-
ment for lymphoma. Compulsory treatment with pro-
phylactic antibiotics was not planned and the use of
granulocyte colony-stimulating factor (G-CSF) was
optional. The staging tests included physical exami-
nation, computed tomography (CT) of the chest,
abdomen and pelvis, bone marrow biopsy and routine
blood chemistry tests. At the end of the chemothera-
py patients underwent the same CT scans and any oth-
er tests which resulted positive at diagnosis.
Study objectives
The aim of the present study was to evaluate the
quality of life of elderly patients with aggressive NHL
treated with anthracycline-containing chemotherapy
in the setting of a clinical trial.
QOL assessment
QOL was assessed by the EORTC-QLQ-C30 question-
naire,18 which has already been used in several studies
in patients with NHL and other types of cancer.19,20 The
EORTC QLQ-C30 is a 30-item questionnaire composed
of multi-item scales and single items that reflect the
multidimensionality of the quality-of-life construct. It
incorporates five functional scales (physical, role, cog-
nitive, emotional, and social), three symptom scales
(fatigue, pain, and nausea and vomiting), and a global
health and quality-of-life scale. The remaining single
items assess additional symptoms commonly reported
by cancer patients (dyspnea, appetite loss, sleep distur-
bance, constipation, and diarrhea), as well as the per-
ceived financial impact of the disease and treatment.
The Italian validated version of the EORTC QLQ-C30 was
used in the present study. QOL scales were calculated
according to the EORTC scoring manual21 and raw scores
were standardized by linear transformation into ranges
from 0 to 100. For the functional scales and the global
QOL scales a higher score represents a better level of
function. For the symptom scales, a higher score corre-
sponds to a higher level of symptoms.
The EORTC-QLQ-C30 questionnaire was adminis-
tered at the time of diagnosis before any treatment
was given, half way through the chemotherapy (before
the day-29 infusion of the P-VEBEC regimen and
before the fourth cycle of the mini-CEOP chemother-
apy) and at the time of restaging (approximately one
month after the end of the chemotherapy). The ques-
tionnaire was administered by a nurse whose task was
to verify the patient’s compliance. The nurse was
instructed to ask the questions with no further com-
ment. Any clarifications requested on the questions
had to be as brief as possible.
Patients were considered eligible for the evaluation
of quality of life if they had been given at least the
baseline and final questionnaire.
Statistical methods
Proportions were compared by Fisher’s exact test.
Comparison of quality of life scores between groups
and at different phases of treatment were performed
using analysis of variance tests for paired samples. A
probability of < 5% was considered statistically sig-
nificant for all evaluations. The software Statistical
Package for Social Sciences (SPSS) for Windows,
release 10.0, was used for all the statistical analyses.
Results
Recruitment
Seventeen out of 40 centers participating in the clin-
ical phase III trial agreed to participate in the QOL
study; these centers provided 76% of all cases includ-
ed in the clinical trial. Pre-therapy questionnaires were
received from 156 patients. Among the 156 patients
who completed the baseline questionnaire 65 patients
did not complete the final one: 30 due to interruption
of the therapy because of toxicity or disease progres-
sion, the remaining 35 due to incompleteness of one
of the two questionnaires or missing questionnaires.    
The group of 91 patients who  also completed the
post-therapy questionnaire are the subject of the pres-
ent report. Sixty-four patients had also completed the
intermediate questionnaire and were available for an
intermediate evaluation. The clinical characteristics of
the 91 patients are shown in Table 1.
Patients were equally distributed in terms of treat-
ment centers so that the prophylactic measures taken
to reduce toxicity of chemotherapy (anti-emetics,
antibiotics) could not have induced a difference
between the two groups (data not shown).
Baseline QOL assessment
Baseline QOL assessement and clinical data were
available for all 91 patients. The values of single QOL
scales are reported in detail in Table 2 and are corre-
lated with the presence of clinical features with known
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adverse prognostic value. Among the evaluated clini-
cal parameters, anemia and IPI were strongly associ-
ated with poorer values of  QOL scales (9 and 10 out
of 16, respectively) while poor performance status
showed an intermediate strength association with
poor QOL results.
Change in QOL during treatment
Analysis of the final QOL assessment showed all
multi and single item scales had improved except diar-
rhea and social activity which had deteriorated slight-
ly. Among the other scales a statistically significant
improvement was observed for pain (p=0.003),
appetite (p=0.006), sleep (p=0.015) and global health
(p=0.027). The results are summarized in Table 3.
An intermediate QOL assessment was also available
for 64 patients. An early improvement was observed
for the pain score (p<0.0001) while a worsening of
nausea and vomiting score (p=0.007) was recorded
after the administration of the first half of treatment.
A delayed improvement was observed for fatigue
(p=0,026) and global health scales (p=0.015; see Fig-
ure 1).
QOL and response to the therapy
Among the 91 patients who completed the QOL
questionnaire both before and after therapy, 50
patients (55%) obtained a complete response (CR), 34
patients (36%) had a partial response (PR) and 7
patients (9%) had no response or progressive disease.
Comparing QOL results between patients in CR with
those in PR or less, the improvement of the variables
which changed positively in the overall population
(pain, appetite, sleep, overall health) was confirmed
only in the first group. Moreover, patients in CR
achieved a benefit in terms of emotional (p=0.01), role
(p=0.05), constipation (p=0,04) and global QOL
(p=0.05) scores (Table 4). On the contrary, in patients
with less than CR, no parameter improved significant-
ly at the end of therapy (data not shown).
No significant differences were found between
patients treated with P-VEBEC and those treated with
mini-CEOP (data not shown).
Discussion
Since the beginning of the 1980s, the idea that cure
of NHL was a reasonable objective even in patients over
65 years old has made much headway. In fact, although
the overall percentages of CR and failure-free survival
(FFS) are lower than those in younger patients, surveys
demonstrate that the percentages of CR in elderly
patients fluctuate between 46 and 77%,3,11 with a strong
possibility of this group maintaining long-lasting remis-
sions. However, these patients have a limited life
expectancy and the price paid by elderly patients in
terms of quality of life to obtain the cure of the disease
has never been verified.
In the present study we evaluated the issue of QOL in
a group of elderly patients with aggressive NHL regis-
tered in a phase III clinical trial by the Intergruppo Ita-
liano Linfomi comparing the feasibility of and respons-
es to two different regimens specifically devised for the
elderly (mini-CEOP vs P-VEBEC) with different timings
and dose intensities.12
A questionnaire which had already been tried and
tested on cancer patients seemed to be the most suit-
able tool. No evaluation of this type on a population of
elderly patients has ever been published. One reason
for this is probably the low reliability of the answers giv-
en. The idea of this questionnaire being proposed to the
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Table 1. Characteristics of the 91 patients in whom QOL
was evaluated.
All pts. (n=91)
Age (years)
Median (Range) 73 (66-85)
N %
Gender
Male 31 34
Female 60 66
Stage
I 3 3.3
II 19 20.9
III 23 23.3
IV 46 50.5
Performance Status
0-1 73 80.2
2-3 18 19.8
Hemoglobin (g/dL)
≥ 12 49 53.8
< 12 42 46.2
Lactate dehydrogenase
≤ normal value 42 46.2
> normal value 49 53.8
Age-adjusted IPI
0-1 47 51.6
2-3 44 48.4
Response
CR 50 54.9
Less than CR 41 45.1
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patients by a nurse (despite the fact that EORTC-QLQ-
C30 was designed for self-compilation) was intended
both to evaluate the patient’s compliance to the ques-
tions and to avoid interference from the patient’s rela-
tives who could condition the replies or even answer on
the patient’s behalf. When interpreting our results, it
should be noted that some symptoms examined by the
EORTC-QLQ30, such as sleeping disturbances, loss of
appetite or the feeling of pain might be influenced by
a depressive state that is not rare in a population of eld-
erly patients; this represents a limitation of the EORTC-
QLQ30 that could be overcome only with the use of a
specific psychologic questionnaire on anxiety and
depression such as the Hospital Anxiety and Depres-
sion (HAD) scale.
The results of the present study demonstrate that the
EORTC-QLQ-C30 questionnaire is also valid when used
on a population of elderly patients. Based on our results
the reliability of the answers was good and supported
by the correspondence of the evaluation of the state of
health of the patients from the answers to question-
naires administered at diagnosis and the IPI. A second
aspect is the coherent and complete overlap of initial
and final answers to the question on financial status.
This result was expected, as the people who were stud-
ied were retired and no longer carried out any profes-
Table 2. Quality of life and clinical parameters at diagnosis.
N Phisycs p Role p Cognitive p Emotional p Social p Fatigue p
Function Function Function Function Activity
Hemoglobin (g/dL)
≥ 12 49 71.0 0.010 74.8 0.010 90.1 0.004 75.5 0.08 84.8 0.005 25.5 0.0001
(41.5-100) (43.2-100) (77.9-100) (56-95) (66.8-100) (4.6-46.4)
< 12 42 53.3 55.5 79.3 66.6 69.8 44.5
(18.0-88.5) (17.5-93.5) (57.6-100) (38-95.3) (39.3-100) (17.3-71.8)
ECOG Performance Status
0-1 73 67.3 0.008 71.2 0.004 86.7 71.4 80.5 0.05 32.5
(34.6-100) (36.8-100) (69.4-100) (46.4-96.4) (55.8-100) (5.9-59.1)
2-4 18 44.4 44.4 78.7 71.2 67.2 41.7
(14.8-73.9) (10.1-78.7) (59-98.3) (48.7-93.8) (40.2-94.3) (20.5-62.9)
Age-Adjusted IPI
0-1 47 71.9 0.007 78.2 0.001 89.1 0.05 76.4 0.030 86.4 0.001 25.7 0.001
(44.2-100) (47.4-100) (75.4-100) (53.8-99) (68-100) (1.5-49.9)
2-4 44 53.1 53.0 81.4 65.5 68.9 43.4
(19.7-86.5) (16.1-89.9) (60.4-100) (40.3-90.7) (39.8-98.0) (19-67.8)
N Pain p Dyspnea p Sleep p Appetite p Global p Global p
disturbance loss Health QOL
Hemoglobin (g/dL)
≥ 12 49 19.1 9.5 0.040 15.7 18.4 0.03 63.2 0.009 62.5 0.01
(0-43.9) (0-29.9) (0-43.6) (0-46.5) (45.9-80.6) (42.5-82.5)
< 12 42 29.4 20.6 30.2 33.3 50.7 49.6
(0-61) (0-50) (0-62.1) (0-67.8) (24.0-77.6) (21.9-77.2)
ECOG Performance Status
0-1 73 18.5 0.0001 13.2 21.5 0.05 20.6 0.004 59.5 0.08 57.5
(0-45.5) (0-37.3) (0-50.6) (0-50) (35.7-83.5) (32.6-82.3)
2-4 18 45.4 20.4 37 44.4 49.0 52.7-2976.5
(21.3-69.5) (0-51) (12.4-61.6) (4.8-84) (32.4-65.7)
Age-Adjusted IPI
0-1 47 16.3 0.009 9.2 0.03 15.6 0.003 19.2 0.05 63.4 0.02 62.6 0.02
(0-40.9) (0-27.2) (0-40.5) (0-49.3) (43.6-83.2) (41.5-83.8)
2-4 44 31.8 20.5 34.1 31.8 51.5 50.3
(1.6-62) (0-51.2) (1.5-66.7) (0-64.7) (26.6-76.4) (23.6-77.1)
The table shows correlations between single baseline QOL scales and the presence of baseline clinical characteristics generally associated with poor outcome. For each scale
the median result is reported with 95% Confidence Interval. p values were assessed by means of between groups non-parametric comparisons tests and are reported when
statistically significant (< 0.05). Constipation, diarrhea, nausea and vomiting and financial scales are not reported because no correlation with any clinical feature was
found.
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sional activity. As far as the analysis of the results is
concerned, the most significant data are that no func-
tional scale showed worse values at the end of the ther-
apy than at diagnosis. This demonstrates that the symp-
toms of the illness have a greater negative influence on
the patient’s life than do the side effects of the thera-
py. This is also confirmed by the data relating to the 64
patients who had completed the intermediate ques-
tionnaire from which it was seen that the QOL is not
further reduced during therapy.
The most significant data are related to the two over-
all questions on health and quality of life; the first
improved for the overall sample of patients, while the
second  improved significantly only in those patients
obtaining a CR. Comparing the group of patients in CR,
in whom scores for 8 out of 16 functional scales
improved, with patients who did not obtain CR, in
whom no score improved, we can conclude that the
there is no cost in terms of QOL for the cure of the dis-
ease. 
Our study did not demonstrate a statistically signifi-
cant advantage in terms of response rate in patients
Table 3. Results of QOL at diagnosis and at the end of
treatment (91 patients).
Start End
QoL of treatment of treatment P
Scales (95% CI) (95% CI)
Functional scales
Physical function 62.8 62.6 ns
(29.5-96.1) (33.0-92.1)
Role function 65.9 71.4 ns
(30.1-100) (40.1-100)
Cognitive function 85.1 86.4 ns
(67.1-100) (68.8-100)
Emotional function 71.4 75.7 ns
(47.0-95.8) (51.4-100)
Social activity 77.8 75.3 ns
(52.3-100) (47.1-100)
Symptom scales
Fatigue 34 30 ns
(8.3-59.7) (7.1-52.9)
Pain 23.8 14.6 0.003
(0-52.3) (0-37.1)
Nausea and vomiting 6.4 6.2 ns
(0-19.3) (0-18.5)
Dyspnea 14.6 13.6 ns
(0-40) (0-34.7)
Sleep disturbance 24.5 16.1 0.015
(0-54.7) (0-40.1)
Appetite loss 25.3 14.7 0.006
(0-57.3) (0-38.6)
Constipation 20.5 17.6 ns
(0-48.1) (0-42.6)
Diarrhea 2.9 5.1 ns
(0-14.7) (0-23)
Financial impact 96.7 96.7 ns
(83.5-100) (83.5-100)
Single item scales
Global Health 57.5 63.7 0.027
(34.5-80.4) (41.5-85.9)
Global QoL 56.5 61.5 ns
(32.0-81.1) (39.7-83.2)
Table 4. QOL scales showing a significant improvement
from baseline levels for patients achieving CR (50
patients). 
QoL Start End p
Scales of treatment of treatment
Functional scales
Role function 64.7 76.7 0.05
(26.4-100) (44.9-100)
Emotional function 70.7 79.7 0.01
(43.7-97.7) (58.3-100)
Symptom scales
Pain 21 11.3 0.02
(0-49.5) (0-30.2)
Sleep disturbance 23.3 11.3 0.007
(0-54.3) (0-29.9)
Appetite loss 28 9 0.0001
(0-61.2) (0-27.2)
Constipation 25.3 17.3 0.04
(0-55.1) (0-46.1)
Single items scales
Global Health 57.3 68 0.011
(34.7-79.9) (49.3-86.7)
Quality of Life 56.7 65.3 0.05
(32.4-81) (45.7-84.9)
Figure 1. Modification of Global Health scale during treat-
ment (64 evaluable patients) showing the mean value at
the start of the treatment, at the  intermediate evaluation
and at the end of therapy; *p=0.039; “p= 0.75 (NS); °p=
0.015. 
Start Intermediate End
59,9*” 60,7°”
66,1*°
90
80
70
60
50
40
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with good initial quality of life compared with those
with poorer QOL.  The hypothesis that the quality of
life estimated with EORTC-QLQ-C30 may have a prog-
nostic role, as described for multiple myeloma,22 is still
an open question. 
Finally a reply cannot be given to which of the two
administered chemotherapy regimens had the better
impact on QOL. This is partly due the small size of the
sample when divided into groups and partly due to a
suggested bias between the data of the P-VEBEC and
mini-CEOP groups which showed a higher prevalence
of patients in CR in the second group. In conclusion our
study demonstrated that QOL assessment is feasible in
elderly patients with NHL and confirmed that future
studies on elderly patients suffering from NHL should
aim to eradicate the disease rather than palliate the
symptoms. We feel that evaluating a larger number of
patients would be very useful in helping to confirm
the results of our study.
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